| [1] |
Jakes RW, Bae SC, Louthrenoo W, et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality [J]. Arthritis Care Res, 2012, 64(2): 159-168.
|
| [2] |
Hoi A, Legel T, Mok CCM, et al. Systemic lupus erythematosus [J]. Lancet, 2024, 403(10441): 2326-2338.
|
| [3] |
Kostopoulou M, Fanouriakis A, Cheema K, et al. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations [J]. RMD Open, 2020, 6(2): e001263.
|
| [4] |
Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease [J]. Kidney Int, 2024, 105(4): S117-S314.
|
| [5] |
Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update [J]. Ann Rheum Dis, 2024, 83(1): 15-29.
|
| [6] |
Houssiau FA, Vasconelos C, D′Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide [J]. Ann Rheum Dis, 2010, 69(1): 61-64.
|
| [7] |
Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis [J]. Arthritis Care Res, 2012, 64(6): 797-808.
|
| [8] |
Mok CC, Hamijoyo L, Kasitanon N, et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus [J]. Lancet Rheumatol, 2021, 3(7): e517-e531.
|
| [9] |
Mok CC, So H, Hamijoyo L, et al. The 2024 APLAR consensus on the management of lupus nephritis [J]. Int J Rheum Dis, 2025, 28(1): e70021.
|
| [10] |
Mok CC, Ho LY, Ying SKY, et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis [J]. Ann Rheum Dis, 2020, 79(8): 1070-1076.
|
| [11] |
Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial [J]. Ann Intern Med, 2015, 162(1): 18-26.
|
| [12] |
Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [J]. Ann Rheum Dis, 2020, 79(6): 713-723.
|
| [13] |
Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [J]. Lancet, 2021, 397(10289): 2070-2080.
|
| [14] |
Saxena A, Ginzler EM, Gibson K, et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial [J]. Arthritis Rheumatol, 2024, 76(1): 59-67.
|
| [15] |
Abdel-Kahaar E, Keller F. Clinical pharmacokinetics and pharmacodynamics of voclosporin [J]. Clin Pharmacokinet, 2023, 62(5): 693-703.
|
| [16] |
van Gelder T, Lerma E, Engelke K, et al. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis [J]. Expert Rev Clin Pharmacol, 2022, 15(5): 515-529.
|
| [17] |
Arriens C, Teng YKO, Ginzler EM, et al. Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis [J]. Arthritis Care Res (Hoboken), 2023, 75(7): 1399-1408.
|
| [18] |
Rovin BH, Solomons N, Pendergraft WF III, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis [J]. Kidney Int, 2019, 95(1): 219-231.
|
| [19] |
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study [J]. Arthritis Rheum, 2012, 64(4): 1215-1226.
|
| [20] |
Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis [J]. Clin J Am Soc Nephrol, 2018, 13(10): 1502-1509.
|
| [21] |
Roveta A, Parodi EL, Brezzi B, et al. Lupus nephritis from pathogenesis to new therapies: an update [J]. Int J Mol Sci, 2024, 25(16): 8981.
|
| [22] |
Rydén-Aulin M, Boumpas D, Bultink I, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe [J]. Lupus Sci Med, 2016, 3(1): e000163.
|
| [23] |
Díaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts [J]. Autoimmun Rev, 2012, 11(5): 357-364.
|
| [24] |
Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry [J]. Arthritis Rheum, 2010, 62(8): 2458-2466.
|
| [25] |
Alshaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis [J]. Eur J Rheumatol, 2018, 5(2): 118-126.
|
| [26] |
Yu X, Chen N, Xue J, et al. Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population [J]. Am J Kidney Dis, 2023, 81(3): 294-306.e1.
|
| [27] |
Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis [J]. Kidney Int, 2022, 101(2): 403-413.
|
| [28] |
Tan M, Xu J, Tan Y, et al. Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China [J]. Kidney Dis (Basel), 2023, 9(3): 218-228.
|
| [29] |
Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis [J]. N Engl J Med, 2020, 383(12): 1117-1128.
|
| [30] |
Furie R, Rovin BH, Houssiau F, et al. Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study [J]. Clin J Am Soc Nephrol, 2022, 17(11): 1620-1630.
|
| [31] |
Zhang K, Qi T, Guo D, et al. Efficacy and safety of belimumab therapy for patients with lupus nephritis: a meta-analysis and a propensity score-matched case-control study [J]. Immun Inflamm Dis, 2023, 11(7): e954.
|
| [32] |
Lin S, Zhang J, You X, et al. Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study [J]. Rheumatology (Oxford), 2025, 64(2): 614-622.
|
| [33] |
Mok CC, Ho LY, Chan KL, et al. Trend of survival of a cohort of Chinese patients with systemic lupus erythematosus over 25 years [J]. Front Med (Lausanne), 2020, 7: 552.
|
| [34] |
Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial [J]. Ann Rheum Dis, 2022, 81(1): 100-107.
|
| [35] |
Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids [J]. Ann Rheum Dis, 2013, 72(8): 1280-1286.
|
| [36] |
Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years [J]. Clin J Am Soc Nephrol, 2006, 1(5): 925-932.
|
| [37] |
Argolini LM, Frontini G, Elefante E, et al. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up [J]. J Nephrol, 2021, 34(2): 389-398.
|
| [38] |
Takeuchi T, Wakasugi N, Uno S, et al. Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis: 5-year interim postmarketing surveillance study in Japan (TRUST) [J]. J Rheumatol, 2021, 48(1): 74-81.
|
| [39] |
Fu Q, Wu C, Dai M, et al. Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up [J]. Ann Rheum Dis, 2022, 81(11): 1549-1555.
|
| [40] |
Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial [J]. Ann Rheum Dis, 2022, 81(10): 1420-1427.
|
| [41] |
Mejia-Vilet JM, Turner-Stokes T, Houssiau F, et al. Kidney involvement in systemic lupus erythematosus: from the patient assessment to a tailored treatment [J]. Best Pract Res Clin Rheumatol, 2023, 37(4): 101925.
|
| [42] |
Rojas-Rivera JE, García-Carro C, Ávila AI, et al. Diagnosis and treatment of lupus nephritis: a summary of the consensus document of the Spanish group for the study of glomerular diseases (GLOSEN) [J]. Clin Kidney J, 2023, 16(9): 1384-1402.
|
| [43] |
Arnold J, Dass S, Twigg S, et al. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab [J]. Rheumatology (Oxford), 2022, 61(12): 4905-4909.
|
| [44] |
Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial [J]. Ann Rheum Dis, 2024, 83(4): 475-487.
|
| [45] |
Huang X, Lin F, Chen H. Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study [J]. Clin Exp Nephrol, 2024, 28(9): 902-909.
|
| [46] |
Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results [J]. Nephrol Dial Transplant, 2021, 36(8): 1474-1483.
|
| [47] |
Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis [J]. Arthritis Rheumatol, 2021, 73(1): 121-131.
|
| [48] |
Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial [J]. Ann Intern Med, 2021, 174(12): 1647-1657.
|
| [49] |
Aranow C, Allaart CF, Amoura Z, et al. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study [J]. Ann Rheum Dis, 2024, 83(11): 1502-1512.
|
| [50] |
Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus [J]. N Engl J Med, 2020, 382(3): 211-221.
|
| [51] |
Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus [J]. Arthritis Rheumatol, 2023, 75(2): 253-265.
|
| [52] |
Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis [J]. Ann Rheum Dis, 2022, 81(4): 496-506.
|
| [53] |
van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study [J]. Lancet, 2018, 392(10155): 1330-1339.
|
| [54] |
van Vollenhoven RF, Kalunian KC, Dörner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus [J]. Ann Rheum Dis, 2022, 81(11): 1556-1563.
|
| [55] |
Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus [J]. Nat Med, 2022, 28(10): 2124-2132.
|
| [56] |
Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up [J]. N Engl J Med, 2024, 390(8): 687-700.
|
| [57] |
Solé C, Royo M, Sandoval S, et al. Precise targeting of autoantigen-specific B cells in lupus nephritis with chimeric autoantibody receptor T cells [J]. Int J Mol Sci, 2024, 25(8): 4226.
|
| [58] |
Wang W, He S, Zhang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial [J]. Ann Rheum Dis, 2024, 83(10): 1304-1314.
|
| [59] |
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management [J]. Blood, 2016, 127(26): 3321-3330.
|
| [60] |
Yan MT, Chao CT, Lin SH, et al. Chronic kidney disease: strategies to retard progression [J]. Int J Mol Sci, 2021, 22(18): 10084.
|
| [61] |
孔维萍，张刘波，刘坚，等. 系统性红斑狼疮及其主要脏器损害的中西医结合诊治[J/OL]. 中华肾病研究电子杂志，2024, 13(1): 9-15.
|
| [62] |
Tse KC, Li FK, Tang S, et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria [J]. Lupus, 2005, 14(12): 947-952.
|
| [63] |
Chang JC, Weiss PF, Xiao R, et al. Use of renin angiotensin aldosterone system inhibitors in children with lupus and time to glucocorticoid discontinuation [J]. Kidney Int, 2022, 102(2): 395-404.
|
| [64] |
Del Vecchio L, Beretta A, Jovane C, et al. A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease [J]. Drugs, 2021, 81(13): 1491-1511.
|
| [65] |
De Nicola L, Cozzolino M, Genovesi S, et al. Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease? [J]. J Nephrol, 2022, 35(6): 1605-1618.
|
| [66] |
Säemann M, Kronbichler A. Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors [J]. Ann Rheum Dis, 2022, 81(5): 614-617.
|